Archive

All Posts

Sep 10, 2026

🧪Questions consumers and clinicians ask TruthTide’s AI engine reveals interests and unknowns

By Rick Polito, Peptides Business Wire editor

Rick Polito, +1

Sep 3, 2026

🧪Gyms provide a pathway to peptides, but can they do it legally?

By Rick Polito, Peptides Business Wire editor

Rick Polito, +1

Aug 27, 2026

Managing the practitioner-pharmacy relationship 🧪

By Rick Polito, Peptides Business Wire editor

Rick Polito, +1

Aug 20, 2026

🧪Lilly lashes out at peptide sellers but will regulators act?

By Rick Polito, Peptides Business Wire editor

Rick Polito, +1

Aug 13, 2026

Longevity makes peptide therapy a "relationship" 🧪

By Rick Polito, Peptides Business Wire editor

Rick Polito, +1

Aug 6, 2026

How peptides are reshaping sports medicine 🧪

By Rick Polito, Peptides Business Wire editor

Edward Mandel, +1

Jul 29, 2026

Is legal access to peptides inevitable? 🧪

By Rick Polito, Peptides Business Wire editor

Edward Mandel, +1

Jul 22, 2026

Committee and Consequence 🧪

FDA’s Pharmacy Compounding Advisory Committee appears peptide-friendly but insiders predict no immediate greenlight. By Rick Polito, Peptides Business Wire editor

Rick Polito